Cannabinoid Clinical Research: The Current State of the Investigative Science in THC, CBD and Others

As CEO of Jabez Pharma Holdings, Inc. Steve Beagle addresses the topic of real investigative science going on in both the regulated and non-regulated areas of cannabinoid science. The continued loosening of restrictions from the FDA, in particular, presents some exciting opportunities to do research science on cannabinoids in humans, but at the same time, ongoing uncertainty and delays present major obstacles to broader market acceptance and expansion. Mr. Beagle will be explaining the current state of cannabinoid science and shedding light on the challenges that drug development companies face as they attempt to navigate this highly dynamic space and formulate drug dosages for the Rx, OTC and nutraceutical markets.

About Steven Beagle | CEO, Jabez Pharma, Inc. Steven Beagle has held senior positions in the pharmaceutical sector for over thirty years. Prior to founding Jabez Pharma in the summer of 2018 he was Senior Director of MSN Pharmaceuticals from 2013-2017 where he headed North American marketing and sales of their API division. He has been credited for the exponential US growth that has now emerged from his work during that time period. Prior to this role, Steve headed publicly-traded Dr. Reddy’s CPS custom chemistry business from 2011 to 2013. Mr. Beagle possesses extensive experience in the pharmaceutical industry, holding key roles not only at MSN and Dr. Reddy’s but also at DSM, BASF, Rohner AG, American Cyanamid and Hovione. He holds a BS from the University of Connecticut and also studied at the Arnold and Marie Schwartz (Brooklyn) College of Pharmacy.